Mode
Text Size
Log in / Sign up
N/A N=391 Randomized Single-blind Treatment

Investigating Superion™ In Spinal Stenosis

Lumbar Spinal Stenosis · Intermittent Claudication

Enrolled (actual)
391
Serious AEs
58.8%
Results posted
Aug 2020
Primary outcome: Primary: Percentage of Subjects With Clinically Significant Improvement in Outcomes — 52.7; 50.2 percentage of subjects

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Superion™ Interspinous Spacer (Device); X-STOP® IPD® Device (Device)
Age
Adult, Older Adult · 45+ yrs
Sex
All
Sponsor
Boston Scientific Corporation
Primary completion
Feb 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Subjects With Clinically Significant Improvement in Outcomes
52.7; 50.2

Summary

The proposed prospective, multi-center, randomized clinical trial is designed to evaluate the safety and effectiveness of the Superion™ ISS compared to the X-STOP® IPD® device in healthy adults suffering from at least 6 months of moderate spinal stenosis symptoms who have been unresponsive to conservative care.

Eligibility Criteria

Inclusion Criteria

  • Male or female subjects ≥ 45 years of age
  • Persistent leg/buttock/groin pain, with or without back pain, that is relieved by flexion activities (example: sitting or bending over a shopping cart)
  • Diagnosis of degenerative spinal stenosis of the lumbar spine, defined as the narrowing of the midline sagittal spinal canal (central) and/or narrowing between the facet superior articulating process (SAP), the posterior vertebral margin (lateral recess), and the nerve root canal (foraminal)
  • Must be able to sit for 50 minutes without pain and to walk 50 feet or more

Exclusion Criteria

  • Axial back pain only
  • Fixed motor deficit
  • Diagnosis of lumbar spinal stenosis which requires any direct neural decompression or surgical intervention other than those required to implant the control or experimental device
  • Unremitting pain in any spinal position
  • Significant peripheral neuropathy or acute denervation secondary to radiculopathy
  • Lumbar spinal stenosis at more than two levels determined pre-operatively to require surgical intervention
  • Significant instability of the lumbar spine as defined by 3mm translation or 5 degrees angulation
  • Sustained pathologic fractures of the vertebrae or multiple fractures of the vertebrae and/or hips
  • Spondylolisthesis or degenerative spondylolisthesis greater than grade 1.0 (on a scale of 1 to 4)
  • Spondylolysis (pars fracture)
  • Morbid obesity, defined as Body Mass Index (BMI) greater than 40kg/m2
  • Insulin-dependent diabetes mellitus
  • Prior surgery of the lumbar spine
  • Cauda equina syndrome (defined as neural compression causing neurogenic bowel or bladder dysfunction)
  • Infection in the disc or spine, past or present
  • Paget's disease at involved segment or metastasis to the vertebra, osteomalacia, or other metabolic bone disease
  • Tumor in the spine or a malignant tumor except for basal cell carcinoma
  • Involved in pending litigation of the spine or worker's compensation related to the back
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00692276). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search